BMJ · 1980 · 35 citations · 4 references
MedicineEndocrinologyNutritionBone MetabolismClinical NutritionMineral MetabolismBone Metabolism DisordersFluoride TherapyFluoride UseMetabolic Bone DiseaseVitamin DVitamin D MetabolismFluoride Metabolism In BoneOsteoid FormationOsteoid VolumeSodium FluorideThyroid Function EvaluationThyroid Function TestingThyroid Function TestsVitamin D Biomarkers
CommentIncreases in osteoid volume with sodium fluoride, calcium, and vitamin D treatment are well documented.Small decreases in mineralisation rate have also been reported.2But osteomalacia in the presence of high plasma 25-OHD concentrations has not been described in patients treated with this regimen.The plasma 1,25-(OH)2D3 concentration in our patient was just below the lower limit of normal, but the total plasma 1,25-(OH)2D (1,25-(OH)2D2-+1,25-(OH)2D3) concentration was probably normal since she was taking vitamin D2 and the radioimmunoassay did not measure plasma 1,25-(OH)2D2.The mechanisms by which fluoride may produce osteomalacia despite high plasma 25-OHD concentrations require further investigation.Possibilities include fluoride-induced end-organ resistance in bone to active vitamin D metabolites or an effect of fluoride on processes of bone mineralisation that are unaffected by vitamin D metabolites.Alternatively, fluoride might affect the metabolism of 25-OHD to other metabolites.Although lack of calcium supplements was probably unimportant in our patient, since the plasma calcium concentration remained above 2 40 mmol,l throughout treatment and dietary calcium intake was adequate, we cannot exclude it as a factor in the development of osteomalacia.Our results indicate that vitamin D in doses that produce high plasma 25-OHD concentrations does not protect against fluoride-induced mineralisation defects and that patients treated with this regimen require careful supervision.Transiliac biopsy provides a sensitive method for diagnosing generalised bone disease such as osteomalacia and may be necessary to detect its development when, as in our patient, plasma biochemical changes are not diagnostic.
4
The effect of diphenylhydantoin on thyroxine metabolism in man
P R Larsen, Arthur J. Atkinson, H. N. Wellman et al. · Journal of Clinical Investigation · 1970 · 120 citations · Full text
Clark T. Sawin, Jerome M. Hershman · The Journal of Clinical Endocrinology & Metabolism · 1976 · 73 citations
Medicine, Endocrinology, Physiology +14
Blood glucose monitors: a laboratory and patient assessment.
David J. Webb, J. M. Lovesay, A. D. Ellis et al. · BMJ · 1980 · 30 citations · Full text
Medicine, Endocrinology, Biosensors +15